Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study
Lorenz Räber, Roland Klingenberg, Dik Heg, Henning Kelbæk, Marco Roffi, David Tüller, Andreas Baumbach, Thomas Zanchin, David Carballo, Miodrag Ostojic, Giulio G Stefanini, Nicolas Rodondi, Clemens von Birgelen, Aris Moschovitis, Thomas Engstrøm, Baris Gencer, Reto Auer, Bernhard Meier, Francois Mach, Thomas F Lüscher, Peter Jüni, Christian M Matter, Stephan Windecker, COMFORTABLE and SPUM-ACS Trial Investigators, Lorenz Räber, Roland Klingenberg, Dik Heg, Henning Kelbæk, Marco Roffi, David Tüller, Andreas Baumbach, Thomas Zanchin, David Carballo, Miodrag Ostojic, Giulio G Stefanini, Nicolas Rodondi, Clemens von Birgelen, Aris Moschovitis, Thomas Engstrøm, Baris Gencer, Reto Auer, Bernhard Meier, Francois Mach, Thomas F Lüscher, Peter Jüni, Christian M Matter, Stephan Windecker, COMFORTABLE and SPUM-ACS Trial Investigators
Abstract
Objectives: The aim of this study was to assess the safety of the concurrent administration of a clopidogrel and prasugrel loading dose in patients undergoing primary percutaneous coronary intervention.
Background: Prasugrel is one of the preferred P2Y12 platelet receptor antagonists for ST-segment elevation myocardial infarction patients. The use of prasugrel was evaluated clinically in clopidogrel-naive patients.
Methods: Between September 2009 and October 2012, a total of 2,023 STEMI patients were enrolled in the COMFORTABLE (Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction [STEMI]) and the SPUM-ACS (Inflammation and Acute Coronary Syndromes) studies. Patients receiving a prasugrel loading dose were divided into 2 groups: 1) clopidogrel and a subsequent prasugrel loading dose; and 2) a prasugrel loading dose. The primary safety endpoint was Bleeding Academic Research Consortium types 3 to 5 bleeding in hospital at 30 days.
Results: Of 2,023 patients undergoing primary percutaneous coronary intervention, 427 (21.1%) received clopidogrel and a subsequent prasugrel loading dose, 447 (22.1%) received a prasugrel loading dose alone, and the remaining received clopidogrel only. At 30 days, the primary safety endpoint was observed in 1.9% of those receiving clopidogrel and a subsequent prasugrel loading dose and 3.4% of those receiving a prasugrel loading dose alone (adjusted hazard ratio [HR]: 0.57; 95% confidence interval [CI]: 0.25 to 1.30, p = 0.18). The HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol concomitantly) bleeding score tended to be higher in prasugrel-treated patients (p = 0.076). The primary safety endpoint results, however, remained unchanged after adjustment for these differences (clopidogrel and a subsequent prasugrel loading dose vs. prasugrel only; HR: 0.54 [95% CI: 0.23 to 1.27], p = 0.16). No differences in the composite of cardiac death, myocardial infarction, or stroke were observed at 30 days (adjusted HR: 0.66, 95% CI: 0.27 to 1.62, p = 0.36).
Conclusions: This observational, nonrandomized study of ST-segment elevation myocardial infarction patients suggests that the administration of a loading dose of prasugrel in patients pre-treated with a loading dose of clopidogrel is not associated with an excess of major bleeding events. (Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction [STEMI] [COMFORTABLE]; NCT00962416; and Inflammation and Acute Coronary Syndromes [SPUM-ACS]; NCT01000701).
Keywords: P2Y(12) inhibitors; ST-segment elevation myocardial infarction; antiplatelet therapy; clopidogrel; prasugrel.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Source: PubMed